Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment.
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. Sakuraba A, et al. Among authors: ashida t. Am J Gastroenterol. 2009 Dec;104(12):2990-5. doi: 10.1038/ajg.2009.453. Epub 2009 Sep 1. Am J Gastroenterol. 2009. PMID: 19724269 Clinical Trial.
Leukocytapheresis for treatment of IBD.
Kohgo Y, Ashida T, Maemoto A, Ayabe T. Kohgo Y, et al. Among authors: ashida t. J Gastroenterol. 2003 Mar;38 Suppl 15:51-4. J Gastroenterol. 2003. PMID: 12698872 Review.
Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Fukuda Y, Takazoe M, Sugita A, Kosaka T, Kinjo F, Otani Y, Fujii H, Koganei K, Makiyama K, Nakamura T, Suda T, Yamamoto S, Ashida T, Majima A, Morita N, Murakami K, Oshitani N, Takahama K, Tochihara M, Tsujikawa T, Watanabe M. Fukuda Y, et al. Among authors: ashida t. Am J Gastroenterol. 2008 Jul;103(7):1721-9. doi: 10.1111/j.1572-0241.2008.01860.x. Epub 2008 Jul 4. Am J Gastroenterol. 2008. PMID: 18616656 Clinical Trial.
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: ashida t. Inflamm Bowel Dis. 2012 Aug;18(8):1480-7. doi: 10.1002/ibd.21886. Epub 2011 Oct 10. Inflamm Bowel Dis. 2012. PMID: 21987418
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: ashida t. J Gastroenterol. 2014 Feb;49(2):254-62. doi: 10.1007/s00535-013-0807-0. Epub 2013 Apr 20. J Gastroenterol. 2014. PMID: 23604570 Clinical Trial.
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Suzuki Y, et al. Among authors: ashida t. Inflamm Bowel Dis. 2015 Sep;21(9):2114-22. doi: 10.1097/MIB.0000000000000475. Inflamm Bowel Dis. 2015. PMID: 26218144 Clinical Trial.
367 results